01.2021

January 7, 2021
|In Portfolio news
|By Ventac Partners

RhoVac AB announced on January 7th, 2021, that the first patient in United Kingdom is enrolled in the company’s clinical phase IIb study in prostate cancer, a study named RhoVac-002 (“BRaVac”). For more information, please visit this link.